C18 NC-TNP
DC60537
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →| CAS No. | Not available |
| Chemical Name | Lipid A3B7C2 |
| Synonyms | A3B7C2 |
| SMILES | CCCCCCCCCCCCOC(=O)CCCCCOC1=CC=C(C=C1OCCCCCC(=O)OCCCCCCCCCCCC)C1=C(N=CN1CCN(CCO)CCO)C1=CC2=C(C=CC=C2)C=C1 |
| Formula | C61H95N3O8 |
| M.Wt | 998.44 |
| Purity | >95% by ELSD-HPLC |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | dong-et-al-2024-multicomponent-synthesis-of-imidazole-based-ionizable-lipids-for-highly-efficient-and-spleen-selective. DOI: 10.1021/jacs.4c00451 |
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| Lipid A3B7C2 | 50 | Ionizable lipid |
| DSPC | 10 | Helper phospholipid |
| Cholesterol | 38.5 | Sterol |
| DMG-PEG2000 | 1.5 | PEG lipid |
| Reported total | 100 | Source values retained |
Component molecular weights and calculated amounts
Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.
| Component | Molecular weight | Molar parts | Normalized mol% | Amount (µmol) | Weight (mg) |
|---|---|---|---|---|---|
| Lipid A3B7C2 | 50.000 | 65.3851 | 65.2831 | ||
| DSPC | 10.000 | 13.0770 | 10.3327 | ||
| Cholesterol | 38.500 | 50.3466 | 19.4665 | ||
| DMG-PEG2000 | 1.500 | 1.9616 | 4.9176 |
Calculated total: 100.0000 mg lipid.
Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.
Literature-reported performance for the cited formulation
Literature-reported98.0%FLuc; 0.1 mg/kg IV; share of measured expression, not percent injected dose · 6 hMain PDF p.8, Fig.4f
Literature-reported18.3-fold higherSame-dose comparator study, 0.1 mg/kg FLuc IV · 6 hMain PDF p.8, Fig.4e
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetdong-et-al-2024-multicomponent-synthesis-of-imidazole-based-ionizable-lipids-for-highly-efficient-and-spleen-selective. DOI: 10.1021/jacs.4c00451 DOI: 10.1021/jacs.4c00451
SI reports IMIL:phosphate = 6:1, which is not automatically a nitrogen:phosphate ratio. Cre reporter recombination is distinguished from CRISPR editing.
SI reports IMIL:phosphate = 6:1, which is not automatically a nitrogen:phosphate ratio. Cre reporter recombination is distinguished from CRISPR editing.